Myocene, the Liège-based sportstech company developing a unique, innovative, cutting-edge device for the objective measurement of muscle fatigue, today announced that it has raised a further €3 million to accelerate its growth, and in particular the international marketing of its device on the European and American markets.
The innovative device developed by Myocene calculates the exact value of the muscular fatigue index in just two minutes. The solution uses a dedicated algorithm to analyze highly precise measurements obtained using a specific sensor and high-precision muscle contraction control. The device can be used both indoors and out, helping top-level athletes to manage their fatigue and improve their performance. It also contributes to technical coaching by offering the possibility of adapting training sessions and rest periods. It also helps prevent the risk of overtraining and injury.
“Since its previous launch in March 2023,” says CEO Jean-Yves Mignolet, “Myocene has signed contracts with top European soccer clubs such as OGC Nice, Sporting Club Braga and Paris-Saint Germain. Over the same period, more than eight hundred and fifty sportsmen and women used it during their training sessions, and more than ten thousand five hundred measurements were taken, enabling fitness trainers to make decisions on player training based on rationally objective information. These measurements have also helped us to refine our device and improve the protocols for its use, while confirming the excellent reliability of the data collected. “
The €3 million fund-raising that the Walloon company has just completed with the participation of InvestSud, Wallonie Entreprendre, Noshaq and the historical founders, part in capital and part in a convertible loan, will be used to accelerate the product’s commercialization on the European and American markets.
“The Myocene system represents a profound change in the way top-level athletes are monitored,” adds Dr Pierre Rigaux, Chairman and Founder. “The tests carried out since its launch have enabled us to establish our technology as a benchmark tool for measuring muscle fatigue in athletes. The three million euros we’ve just raised will enable us to look forward with confidence to growth in Europe and the launch of Myocene on the US market in 2025, for which we now have the highest hopes,” he concludes.